Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic
Super-response to guselkumab is linked to distinct baseline features. Despite differences in PASI outcomes, treatment persistence was similar across groups. These findings underscore the value of early identification of super-responders and support personalized treatment strategies in clinical practice.
Authors
- M Tichý (ORCID: https://orcid.org/0000-0002-4925-2634)
- Martina Kojanová (ORCID: https://orcid.org/0000-0001-9890-9965)
- Alena Machovcová (ORCID: https://orcid.org/0000-0003-0550-1253)
- Petr Arenberger (ORCID: https://orcid.org/0000-0002-4800-5877)
- Jorga Fialová (ORCID: https://orcid.org/0000-0001-6241-6130)
- Petra Cetkovská (ORCID: https://orcid.org/0000-0002-8807-6768)
- Jiří Štork (ORCID: https://orcid.org/0000-0002-8505-3560)
- Spyridon Gkalpakiotis (ORCID: https://orcid.org/0000-0002-6956-5961)
- Daniela Pejrilova
- Tomáš Doležal (ORCID: https://orcid.org/0000-0002-6074-8294)
Institutions
- Charles University (CZ)
- University Hospital in Motol (CZ)
- University Hospital Olomouc (CZ)
- Apigenex (Czechia) (CZ)
- University Hospital Kralovske Vinohrady (CZ)
- General University Hospital in Prague (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1111/ijd.70126
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00